We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





New Study Provides Encouraging Results on Use of Ivermectin for Reducing Viral Transmission in Patients with Mild COVID-19

By HospiMedica International staff writers
Posted on 20 Jan 2021
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission.

The study, led by the University of Navarra Clinic (Pamplona, Spain) and the Barcelona Institute for Global Health (ISGlobal; Barcelona, Spain), warrants further exploration in larger clinical trials. More...
Ivermectin is an antiparasitic drug that has been shown to reduce SARS-CoV-2 replication in vitro (in cell lines), albeit at concentrations that exceed those recommended for human use. This, together with preliminary results from a trial in humans that used data of dubious origin and was never peer-reviewed, prompted the use of ivermectin in many Latin-American countries despite the lack of reliable evidence on its efficacy in treating or preventing infection.

In the pilot study performed with COVID-19 patients, the team evaluated whether the maximal dose of ivermectin recommended in Europe could have an impact on viral transmission when administered within the first days after symptom onset. The research team gave one single dose of ivermectin or placebo to 24 patients with confirmed infection and mild symptoms, within the first 72 hours after the first symptoms started. Nasal swabs and blood samples were taken at the moment of enrolment and one, two and/or three weeks after treatment. Seven days after treatments, no difference was observed in the percentage of PCR-positive patients (100% of patients were positive in both groups).

However, the mean viral load in the ivermectin-treated group was lower (around 3x lower at four days and up to 18x lower at seven days post-treatment), although the difference was not statistically significant. Treated patients also showed a reduced duration of certain symptoms (of 50% for loss of smell and taste and of 30% for cough). All patients developed virus-specific IgG but, again, the mean level of antibodies in the treated group was lower than in the placebo group. The fact that there was no effect on duration of symptoms or makers associated with inflammation suggests that ivermectin may act through mechanisms that do not involve a possible anti-inflammatory effect. The researchers believe it could be interfering with viral entry in the cells, as suggested by another study performed in hamsters.

“Many efforts are focusing on developing treatments for COVID-19, but few are addressing how to reduce viral transmission,” said study coordinator Carlos Chaccour, researcher at ISGlobal and physician at the University of Navarra Clinic. “Our findings are in line with those from recent assays conducted in Bangladesh and Argentina. Although our study is small and it is too early to draw conclusions, the trends observed in viral loads, symptom duration and antibody levels are encouraging and warrant further exploration in larger clinical trials with a higher diversity of patients.”

Related Links:
University of Navarra Clinic
Barcelona Institute for Global Health



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Sling
GoComfort
New
Anesthesia Cart
UTGSU-333369-DKB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: the deep tissue in vivo sound printing (DISP) platform, which combines ultrasound with low-temperature–sensitive liposomes loaded with crosslinking agents (Photo courtesy of Elham Davoodi and Wei Gao/Caltech)

New Ultrasound-Guided 3D Printing Technique to Help Fabricate Medical Implants

3D bioprinting technologies hold considerable promise for advancing modern medicine by enabling the production of customized implants, intricate medical devices, and engineered tissues designed to meet... Read more

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.